Studies Highlight Role of Stem Cell Transplant Procedures
Results from four studies help answer questions about stem cell transplant procedures in treating various hematologic malignancies. Research presented today at the 52nd Annual Meeting of the American Society of Hematology (ASH), held in Orlando, FL, reveals there is no increase in overall cancer risk in people who donate stem cells and that the use of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.
While research shows the use of an allogeneic stem cell transplant following an autologous stem cell transplant does not improve progression-free survival in patients with standard risk multiple myeloma, scientists have found a new treatment that may help prevent chronic graft-versus-host disease, a serious complication of stem cell transplantation.
"Major advances have been made in stem cell transplantation, and studies such as these provide further understanding of the many questions and unknowns remaining in this rapidly evolving field of research," said Armand Keating, MD, vice president of ASH and professor of Medicine, director of the Division of Hematology, and Epstein Chair in Cell Therapy and Transplantation at the University of Toronto. "Results from these studies allow us to continuously improve treatment regimens and manage complications for our patients with multiple blood cancers who require stem cell transplants."